| Rapid, reversible activation of AgRP neurons drives feeding behavior in mice MJ Krashes, S Koda, CP Ye, SC Rogan, AC Adams, DS Cusher, ... The Journal of clinical investigation 121 (4), 1424-1428, 2011 | 1464 | 2011 |
| SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 P Chen, A Nirula, B Heller, RL Gottlieb, J Boscia, J Morris, G Huhn, ... New England Journal of Medicine 384 (3), 229-237, 2021 | 1436 | 2021 |
| Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial RL Gottlieb, A Nirula, P Chen, J Boscia, B Heller, J Morris, G Huhn, ... Jama 325 (7), 632-644, 2021 | 1019 | 2021 |
| Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice M Jaskelioff, FL Muller, JH Paik, E Thomas, S Jiang, AC Adams, E Sahin, ... Nature 469 (7328), 102-106, 2011 | 1014 | 2011 |
| Neutralizing monoclonal antibodies for treatment of COVID-19 PC Taylor, AC Adams, MM Hufford, I De La Torre, K Winthrop, RL Gottlieb Nature Reviews Immunology 21 (6), 382-393, 2021 | 710 | 2021 |
| Bamlanivimab plus etesevimab in mild or moderate Covid-19 M Dougan, A Nirula, M Azizad, B Mocherla, RL Gottlieb, P Chen, C Hebert, ... New England Journal of Medicine 385 (15), 1382-1392, 2021 | 665 | 2021 |
| An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice WL Holland, AC Adams, JT Brozinick, HH Bui, Y Miyauchi, CM Kusminski, ... Cell metabolism 17 (5), 790-797, 2013 | 558 | 2013 |
| The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... Science translational medicine 13 (593), eabf1906, 2021 | 410 | 2021 |
| Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21 Y Li, K Wong, A Giles, J Jiang, JW Lee, AC Adams, A Kharitonenkov, ... Gastroenterology 146 (2), 539-549. e7, 2014 | 304 | 2014 |
| Interplay between FGF21 and insulin action in the liver regulates metabolism B Emanuelli, SG Vienberg, G Smyth, C Cheng, KI Stanford, M Arumugam, ... The Journal of clinical investigation 124 (2), 515-527, 2014 | 292 | 2014 |
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue AC Adams, C Yang, T Coskun, CC Cheng, RE Gimeno, Y Luo, ... Molecular metabolism 2 (1), 31-37, 2013 | 286 | 2013 |
| A metabolic prosurvival role for PML in breast cancer A Carracedo, D Weiss, AK Leliaert, M Bhasin, VCJ De Boer, G Laurent, ... The Journal of clinical investigation 122 (9), 3088-3100, 2012 | 283 | 2012 |
| Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo FM Fisher, JL Estall, AC Adams, PJ Antonellis, HA Bina, JS Flier, ... Endocrinology 152 (8), 2996-3004, 2011 | 271 | 2011 |
| Inventing new medicines: the FGF21 story A Kharitonenkov, AC Adams Molecular metabolism 3 (3), 221-229, 2014 | 255 | 2014 |
| Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice N Douris, DM Stevanovic, FM Fisher, TI Cisu, MJ Chee, NL Nguyen, ... Endocrinology 156 (7), 2470-2481, 2015 | 217 | 2015 |
| FGF21 Requires βklotho to Act In Vivo AC Adams, CC Cheng, T Coskun, A Kharitonenkov PloS one 7 (11), e49977, 2012 | 212 | 2012 |
| Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial MS Cohen, A Nirula, MJ Mulligan, RM Novak, M Marovich, C Yen, ... Jama 326 (1), 46-55, 2021 | 205 | 2021 |
| A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss MK Badman, AR Kennedy, AC Adams, P Pissios, E Maratos-Flier American Journal of Physiology-Endocrinology and Metabolism 297 (5), E1197-E1204, 2009 | 197 | 2009 |
| LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys AC Adams, CA Halstead, BC Hansen, AR Irizarry, JA Martin, SR Myers, ... PloS one 8 (6), e65763, 2013 | 176 | 2013 |
| Discrete aspects of FGF21 in vivo pharmacology do not require UCP1 RJ Samms, DP Smith, CC Cheng, PP Antonellis, JW Perfield, ... Cell reports 11 (7), 991-999, 2015 | 160 | 2015 |
Jeffrey S. FlierHigginson Professor of Medicine and Neurobiology, Harvard Medical School在 Hms.Harvard.edu 的电子邮件经过验证
